THE EFFECT OF STATIN THERAPY ON MONOCYTE SUBPOPULATIONS IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY. (June 2018)

• Record Type: Journal Article
• Authors: Kologrivova, I.; Suslova, T.; Koshelskaya, O.; Vinnitskaya, I.
• Is Part Of: Journal of hypertension. Volume 36(2018)Supplement 1
• Publication Date: 2018-06
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000539248.89168.74
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Association of arterial hypertension with obesity is an acknowledged risk factor of the development of coronary artery disease (CAD). Statins represent golden standard of management dyslipidemia in these patients. One of the mechanisms linking arterial hypertension, obesity and atherosclerosis is a low-grade inflammation. Recently it had been shown that minor subpopulations of monocytes with phenotype CD14loCD16+ and CD14+CD16+ are highly proatherogenic. The objective of the study was to evaluate influence of statins on composition of monocyte population in obese patients with arterial hypertension. Design and method: A total number of 16 patients (7 men, 9 women; age 58.5 (54.8; 62.5) years; body mass index 30.9 (29.1; 32.8)) were recruited in the study. Among them 9 patients received statin therapy (atorvastatin in 7 patients (mean dose 18.6 mg); rosuvastatin in 2 patients (mean dose 10 mg)); 7 patients did not take statins. Lipid profile was determined by standard method, including measurement of total cholesterol, triglicerides, low density lipoproteins cholesterol (LDL-C) concentrations, and calculation of high density lipoproteins cholesterol (HDL-C)concentration and LDL/HDL ratio. Numbers of classical CD14hiCD16lo, non-classical CD14loCD16+ and intermediate CD14+CD16+ monocytes were determined by flow cytometry. Results: Statin therapy allowed to obtain target values of LDL-C in the majority of patients in the study (2.9 (2.5; 3.4) mM vs. 3.6 (3.1; 4.3) mM in patients who did not take statins). Patients receiving statin therapy were characterized by lower numbers of CD14loCD16+ monocytes (5.4 (3.6; 8.1)% vs. 10.9 (8.5; 18.3)%; p = 0.016) and higher frequency of CD14hiCD16lo monocytes compared to patients without statins in the course of medication (89.4 (82.9; 92.3)% vs. 79.3 (73.8; 84.4)%; p = 0.023). No differences were revealed in numbers of CD14+CD16+ monocytes. In total group of patients we revealed negative association between numbers of CD14loCD16+ monocytes and LDL-C concentrations in women, but not in men (r = 0.857; p = 0.014). Conclusions: Statin therapy in patients with arterial hypertension and obesity is associated with low numbers of proatherogenic CD14loCD16+ monocytes and higher frequency of classical CD14hiCD16lo monocytes, which may be related to lipid-lowering effects of statins.